Glycoprotein IIb/IIIa inhibitors for the neurointerventionalist. Issue 1 (February 2022)

• Record Type: Journal Article
• Authors: Simonato, Davide; Borchert, Robin J; Labeyrie, Marc-Antoine; Fuschi, Maurizio; Thibault, Lucie; Henkes, Hans; Fiorella, David; Tan, Benjamin YQ; Yeo, Leonard LL; Makalanda, Hegoda LD; Wong, Ken; Bhogal, Pervinder
• Is Part Of: Interventional neuroradiology. Volume 28:Issue 1(2022)
• Page Start: 84
• Page End: 91
• Publication Date: 2022-02
• Subjects: Platelets -- hemorrhage -- thrombectomy -- stroke -- aneurysm; Nervous system -- Interventional radiology -- Periodicals; Nervous system -- Radiography -- Periodicals; Nervous System Diseases -- Periodicals -- radiography; Neuroradiography -- Periodicals; Radiography, Interventional -- Periodicals; Nervous system -- Radiography; Periodicals; 617.4805
• DOI: 10.1177/15910199211015038
• Languages: English
• ISSNs: 1591-0199

Abstract

Antiplatelet therapies are commonly used in neurointerventional procedures. However, specific guidelines for their use in these settings is lacking and it can often be difficult to balance the potential risks and benefits of these medications. Considering the continued growth and adoption of neurointerventional procedures, it is crucial to understand the properties of these agents in order to use them safely. Large-scale clinical trials are still needed to clarify many of these aspects for this emerging field. However, the existing literature already provides insight into which antiplatelet drugs are of benefit to the neurointerventionalist as well as their associated risks of ischemic and hemorrhagic complications. Hence, this review focuses on the applications of GPIIb/IIIA inhibitors to neurointerventional procedures.